IVERIC bio (ISEE) Scheduled to Post Earnings on Thursday

IVERIC bio (NASDAQ:ISEE) will release its earnings data before the market opens on Thursday, August 1st.

IVERIC bio (NASDAQ:ISEE) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. On average, analysts expect IVERIC bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:ISEE traded up $0.05 during trading hours on Tuesday, reaching $1.22. The company had a trading volume of 595 shares, compared to its average volume of 82,198. The company has a market capitalization of $48.94 million, a price-to-earnings ratio of -0.72 and a beta of 1.18. The stock has a 50-day moving average price of $1.25. IVERIC bio has a twelve month low of $1.02 and a twelve month high of $2.61.

In other IVERIC bio news, insider Glenn Sblendorio acquired 25,000 shares of the company’s stock in a transaction on Friday, May 10th. The shares were purchased at an average cost of $1.48 per share, with a total value of $37,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is currently owned by company insiders.

A number of research firms have commented on ISEE. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research raised shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research note on Tuesday, June 4th.

About IVERIC bio

IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).

Featured Story: Equal Weight Rating

Earnings History for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.